Galena Biopharma Presents Phase 2 Trial Design for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (Trastuzumab) at the 34th Annual CTRC-American Association for Cancer ResearchSan Antonio Breast Cancer Symposium

LAKE OSWEGO, Ore., Dec. 9, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today presented the trial design for the upcoming Phase 2 combination trial with NeuVax™ (E75 plus GM-CSF) and Herceptin® (trastuzumab; Genentech/Roche) at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event is being held December 6-10, 2011 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.